Rohtak (Haryana): The first part of phase-1 of Covaxin human trial completed on Saturday at Post-Graduate Institute (PGI) of Medical Sciences, Rohtak, said Dr Savita Verma, principal investigator of the vaccine trial team.
Dr Verma said that six people were administered the vaccine on Saturday under the second part of phase-1.
"First part of phase-1 of vaccine trial (Covaxin) has been completed. 50 people across India were administered the vaccine and the results were encouraging. Six people were administered vaccine on Saturday under second part of phase-1," she said.
READ: Phase-I human clinical trial of potential COVID-19 vaccine: Man given first dose at AIIMS
Human trials of Covaxin, India's first vaccine candidate against coronavirus, began at PGI Rohtak on July 17. Three volunteers were administered Covaxin on that day.
COVID-19 vaccine candidate Covaxin, developed by the Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV), had recently got the nod for human clinical trials from the Drugs Controller General of India (DCGI).
AIIMS-Delhi is also among the 12 sites selected by the Indian Council for Medical Research (ICMR) for conducting phase I and II randomised, double-blind, placebo-controlled clinical trials of Covaxin.
WATCH: Bharat Biotech developed India's first COVID-19 vaccine candidate
